Year End Conf Call Details

RNS Number:5259J
Skyepharma PLC
02 April 2003


For Immediate Release                                           April 2, 2003



               SkyePharma to Host 2002 Year-End Earnings Results
                  Conference Call - NB Change to UK Call Time



NEW YORK & LONDON, April 2, 2003 -- SkyePharma PLC (Nasdaq: SKYE; LSE: SKP)
announced today that the Company will host a conference call today to review the
financial results for the year ended December 31, 2002.



Investors and other interested parties may access the conference call, hosted by
Michael Ashton, SkyePharma's Chief Executive Officer, at 10:00 a.m. (EST)
Wednesday, April 2, 2003, by dialling [phone] for US participants and at
4.00 p.m. (BST) by dialling [phone] for International participants.  The
slides of the presentation will be available on the Company's website at
www.skyepharma.com under the Investor Relations tab.



For those who cannot listen to the live broadcast, a replay will be available
shortly after the conference call by dialling [phone] for US participants
and [phone] for International participants and entering Access Code
678162.  Alternatively, interested parties can access an archived version of the
live webcast, which will have been held at 10.00 a.m. (GMT), on the Company's
website at www.skyepharma.com under the Investor Relations tab.



SkyePharma PLC uses its world-leading drug delivery technologies to develop
easier-to-use and more effective formulations of drugs. The majority of
challenges faced in the formulation and delivery of drugs can be addressed by
one of the Company's proprietary technologies in the areas of oral, injectable,
inhaled and topical delivery, supported by enhanced solubilisation capabilities.
For more information, visit http://www.skyepharma.com.



This press release may contain forward-looking statements regarding SkyePharma
PLC.  Actual results may differ materially from those described in the press
release as a result of a number of factors, including but not limited to the
following: There can be no assurance that any product in the SkyePharma product
pipeline will be successfully developed or manufactured, or that final results
of human clinical trials will result in the regulatory approvals required to
market products, or that final regulatory approval will be received in a timely
manner, if at all, or that patient and physician acceptance of these products
will be achieved.  The Company undertakes no obligation to revise or update any
such forward-looking statement to reflect events or circumstances after the date
of this release.



For further information please contact:


SkyePharma PLC                                              [phone]
Michael Ashton, Chief Executive Officer
Peter Laing, Director of Corporate Communications

Sandra Haughton, US Investor Relations                      [phone]






                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

MSCITMPTMMJMMAJ